Literature DB >> 17914411

Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.

C M Butcher, U Hahn, L B To, J Gecz, E J Wilkins, H S Scott, P G Bardy, R J D'Andrea.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914411     DOI: 10.1038/sj.leu.2404971

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  21 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 2.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

3.  Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.

Authors:  Ana Paula Azevedo; Susana N Silva; Alice Reichert; Fernando Lima; Esmeraldina Júnior; José Rueff
Journal:  Biomed Rep       Date:  2017-09-05

4.  Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.

Authors:  Serge Carillo; Laurent Henry; Eric Lippert; François Girodon; Isabelle Guiraud; Céline Richard; Frédérique Dubois Galopin; Cedric Cleyrat; Eric Jourdan; Robert Kralovics; Sylvie Hermouet; Thierry Lavabre-Bertrand
Journal:  J Mol Diagn       Date:  2011-05       Impact factor: 5.568

Review 5.  Molecular aspects of myeloproliferative neoplasms.

Authors:  François Delhommeau; Dorota Jeziorowska; Christophe Marzac; Nicole Casadevall
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

6.  Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.

Authors:  Todd S Laughlin; Alison R Moliterno; Brady L Stein; Paul G Rothberg
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

Review 7.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

8.  JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis.

Authors:  Jun Xia; Mi-Ze Lu; Yuan-Qiang Jiang; Guo-Hua Yang; Yun Zhuang; Hong-Li Sun; Yun-Feng Shen
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

9.  A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation.

Authors:  Lequn Zhao; Hongyun Dong; Cheng Cheng Zhang; Lisa Kinch; Mitsujiro Osawa; Michelina Iacovino; Nikolai V Grishin; Michael Kyba; Lily Jun-shen Huang
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

10.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.